北京商报讯（记者 王寅浩 宋雨盈）1月30日，科兴制药发布2025年业绩预告，预计2025年实现归属于母 公司所有者的净利润为1.35亿—1.75亿元，同比增加328.83%—455.89%。预计归属于母公司所有者的扣 除非经常性损益的净利润为5000万—7000万元，同比增加41.83%—98.56%。 根据公告，2025年，科兴制药积极开拓海外市场，实现了海外收入增长，推动营收持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。 ...

2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 格隆汇1月30日丨科兴制药(688136.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母 公司所有者的净利润为13,500万元至17,500万元，与上年同期（法定披露数据）相比，将增加10,352万 元至14,352万元，同比增加328.83%至455.89%。预计归属于母公司所有者的扣除非经常性损益的净利润 为5,000万元至7,000万元，与上年同期（法定披露数据）相比，将增加1,475万元至3,475万元，同比增加 41.83%至98.56%。 ...

每经AI快讯，1月30日，科兴制药(688136.SH)公告称，预计2025年归属于上市公司股东的净利润为1.35 亿元至1.75亿元，同比增长328.83%-455.89%。业绩变动主要原因系公司积极开拓海外市场，实现海外 收入强劲增长，推动营业收入持续增长，带动净利润大幅上升。 （文章来源：每日经济新闻） ...

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，科兴制药1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为1.35亿元~1.75亿元，与上年同期相比，将增加约1.04亿元至1.44亿元，同比增加328.83%~455.89%。 业绩变动主要原因是，2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收 入持续增长，归属于母公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提 升。报告期内非经常性损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子 公司所致。 （记者 曾健辉） ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-009 科兴生物制药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 （1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测 算，预计 2025 年年度实现归属于母公司所有者的净利润为 13,500 万元至 17,500 万元，与上年同期（法定披露数据）相比，将增加 10,352 万元至 14,352 万元， 同比增加 328.83%至 455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为 5,000 万元 至 7,000 万元，与上年同期（法定披露数据）相比，将增加 1,475 万元至 3,475 万元，同比增加 41.83%至 98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：5,690.26 万元。归属于母公司所有者的净利润：3,148.09 万元。归属于母公司所有者的扣除非经常性损益的净 ...

南财智讯1月30日电，科兴制药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 13500万元—17500万元，同比预增328.83%—455.89%；预计2025年全年归属于上市公司股东的扣除非 经常性损益的净利润为5000万元—7000万元，同比预增41.83%—98.56%。本期业绩变化的主要原因： 2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 ...

科兴制药公告，预计2025年年度实现归属于母公司所有者的净利润为1.35亿元至1.75亿元，同比增加 328.83%至455.89%。预计归属于母公司所有者的扣除非经常性损益的净利润为5000万元至7000万元， 同比增加41.83%至98.56%。上年同期，归属于母公司所有者的净利润为3148.09万元，归属于母公司所 有者的扣除非经常性损益的净利润为3525.43万元。本期业绩变化的主要原因为公司积极开拓海外市 场，实现了海外收入的强劲增长，推动公司营业收入持续增长。 ...

Core Viewpoint - The article emphasizes the increasing urgency for effective antiviral interventions in response to the rising influenza activity, particularly among children and adolescents, highlighting the role of innovative biopharmaceutical solutions from companies like Sinovac Biotech in combating respiratory viral infections [1][12]. Group 1: Antiviral Strategies - Influenza, caused by the influenza virus, spreads rapidly, necessitating early activation of the body's immune defenses, with interferon serving as a natural first line of defense against viral infections [2]. - Human interferon α1b, a domestically developed type I interferon, exhibits broad-spectrum antiviral activity and mild immunomodulatory properties, with Sinovac being one of the early companies engaged in its research and production [2]. Group 2: Clinical Applications of Interferon - Interferon plays a crucial role in treating viral respiratory infections, with early intervention being emphasized as key to effective antiviral therapy [3]. - The clinical use of Sinovac's interferon α1b (brand name: Sai Ruojin) has been validated over three decades, particularly in treating viral pneumonia and bronchiolitis in children, demonstrating efficacy in controlling viral load and alleviating symptoms [5]. Group 3: Innovation in Antiviral Solutions - Sinovac is advancing the development of GB05, an inhalation solution of human interferon α1b, aimed at addressing the limitations of injection methods for respiratory infections, particularly for conditions like respiratory syncytial virus (RSV) [9][10]. - GB05 features molecular design innovations that enhance stability and safety, making it suitable for pediatric use, and its delivery method allows for targeted action in the respiratory tract while minimizing systemic exposure [10]. Group 4: Commitment to Quality and Social Responsibility - Sinovac prioritizes drug quality through a stringent quality management system, ensuring effective clinical outcomes from the development process to final product [8]. - The company engages in academic exchanges to promote the rational use of interferon, emphasizing early and adequate treatment principles to improve the management of viral respiratory infections in primary healthcare settings [8]. Group 5: Future Directions - The article concludes that flu prevention requires a multifaceted approach, and Sinovac is committed to continuous innovation in antiviral drug development to meet unmet clinical needs, contributing to public health initiatives [12].

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced fluctuations, with a recent decline of 2.06%, while the company shows a year-to-date increase of 11.34% in stock price, indicating mixed market sentiment towards its performance and potential [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, showing a significant year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has seen a net outflow of 8.37 million yuan from major funds, with significant buying and selling activity from large orders [1]. Dividend Distribution - Kexing Pharmaceutical has distributed a total of 51.54 million yuan in dividends since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the second-largest shareholder with 2.0621 million shares, a decrease of 1.6069 million shares from the previous period [3]. - Other significant changes in institutional holdings include an increase in shares held by Fortune Tianhui Growth Mixed A/B and a decrease in shares held by Fortune Precision Medical Flexible Allocation Mixed A [3].

Group 1 - The Hang Seng Technology Index increased by 1.93% and the Hang Seng Index rose by 1.32% [1] - Notable stock performances include: Zhaoyi Innovation up by 45.06%, Dali Group Holdings up by 13.35%, and Rongchang Bio up by 8.84% [1] - Declining stocks include: Times Angel down by 4.96%, Master Kong Holdings down by 4.18%, and CIMC Enric down by 3.72% [1]